This bill would change the Federal Food, Drug, and Cosmetic Act to give a period of market exclusivity to botanical drugs. The bill was introduced in the House on 2026-08-27 and referred to the House Committee on Energy and Commerce. Sponsors listed are Representatives Lauren Boebert and Derrick Van Orden. No publicly available information on the exact length of exclusivity, specific definitions, or other provisions is included in the provided material.
If enacted, the change would affect how botanical drug products are treated under federal drug rules. Companies that make or plan to make botanical drugs could be affected by new exclusivity rights. Consumers, prescribers, and pharmacies might see changes in product availability or company behavior. No publicly available information describes specific effects or timelines.
No publicly available information about government costs, expected savings, or changes to private-sector costs is included in the provided material.
No publicly available information on proponents' statements, findings, or formal arguments is included in the provided material. The bill sponsor names are Lauren Boebert and Derrick Van Orden.
No publicly available information on opponents' statements, findings, or formal arguments is included in the provided material.